Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate CardiolRx for the Treatment of Pericarditis

Toronto, ON– February 15, 2024– Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the“Company”), a clinical-stage life sciences company focused on the research and clinical development of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials